Italia markets closed
FTSE MIB
34.492,41 +44,84 (+0,13%) Dow Jones
38.686,32 +574,84 (+1,51%) Nasdaq
16.735,02 -2,06 (-0,01%) Nikkei 225
38.487,90 +433,77 (+1,14%) Petrolio
77,18 -0,73 (-0,94%) Bitcoin EUR
62.225,09 +262,32 (+0,42%)
NBIX Jun 2024 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 09:30AM EDT
| Chiusura precedente | 2,7500 |
| Aperto | 2,7500 |
| Denaro | 1,6000 |
| Domanda | 6,0000 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 2,7500 - 2,7500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 69 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.